Table 1.

(A) The rates of reduction (k) in B14 cells of the doxyl stearate nitroxides (5-DS, Met-12-DS, and 16-DS) applied alone at the final concentration of 80 μM or together with 1 μM doxorubicin (DOX). The data are presented as means ± SD of at least three independent experiments. (B) Half-reduction times in B14 cells of the doxyl stearate nitroxides (5-DS, Met-12-DS, and 16-DS) applied alone at the final concentration of 80 μM or together with 1 μM doxorubicin (DOX). The data are presented as means ± SD of at least three independent experiments.

(A)
Compound(s)	The Rate of Nitroxide Reduction (k) ± SD	Statistical Significance
5-DS	−0.7887 ± 0.0638	vs. other DSs applied alone	p < 0.05 vs. Met-12-DS
Met-12-DS	−0.5064 ± 0.1347		p < 0.05 vs. 5-DS
16-DS	−0.6970 ± 0.1334		n.s.
1 μM DOX + 5-DS	−0.649 ± 0.1138	vs. the same DS applied alone	n.s.
1 μM DOX + Met-12-DS	−0.4707 ± 0.1328		n.s.
1 μM DOX + 16-DS	−0.5877 ± 0.1082		n.s.
(B)
Compound(s)	Half-Reduction Time of a Nitroxide (t ½) [min] ± SD	Statistical Significance
5-DS	63.66 ± 5.01	vs. other DSs applied alone	p < 0.01 vs. Met-12-DS
Met-12-DS	104.42 ± 26.04		p < 0.01 vs. 5-DS; p < 0.05 vs. 16-DS
16-DS	73.66 ± 15.19		p < 0.05 vs. Met-12-DS
1 μM DOX + 5-DS	78.82 ± 13.62	vs. the same DS applied alone	n.s.
1 μM DOX + Met-12-DS	113.52 ± 31.32		n.s.
1 μM DOX + 16-DS	87.34 ± 16.50		n.s.

n.s.—not significant.